| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Gross Margin | 9.02% | -85.15% | -0.43% | -8.03% | -14.73% |
| Operating Margin | -9312.55% | -12057.23% | -6466.48% | -10089.53% | -4897.89% |
| EBITDA Margin | -9012.26% | -11634.83% | -6250.74% | -9769.20% | -4588.75% |
| Net Margin | -9551.87% | -15293.78% | -6513.41% | -12582.79% | -8210.53% |
| Current Ratio | 14.81 | 0.71 | 0.40 | 1.40 | 0.10 |
| Quick Ratio | 14.81 | 0.71 | 0.40 | 1.40 | 0.10 |
| Debt / Equity | — | — | — | — | — |
| ROE | -56.36% | -720.88% | 674.64% | -425.43% | 38.58% |
| ROA | -52.91% | -329.31% | -199.67% | -237.23% | -261.99% |
| Asset Turnover | 0.01 | 0.02 | 0.03 | 0.02 | 0.03 |
| Book Value / Share | 24.12 | 1028.69 | -1.31 | 0.29 | -14.17 |
Aclarion Inc. is a healthcare technology company that develops innovative diagnostic solutions for spine-related conditions, particularly low back and neck pain. The company combines magnetic resonance spectroscopy (MRS) imaging with proprietary augmented-intelligence algorithms to create software-as-a-service (SaaS) solutions that help physicians personalize treatment plans and optimize clinical outcomes. The company's primary offering is the NOCISCAN Suite, which uses MRS capabilities to noninvasively analyze the chemical composition of intervertebral discs in the spine. Aclarion's suite includes the NOCISCAN MRS Exam Protocol for standard lumbar MRI exams, the NOCISCAN Post-Processor Suite with NOCICALC and NOCIGRAM applications that process spectroscopy data and calculate degenerative pain biomarkers, and complementary imaging data transfer platforms. By leveraging artificial intelligence to assist in quality control processes and proprietary biomarkers, Aclarion aims to address unmet clinical needs in musculoskeletal pain management and help patients achieve improved health outcomes and pain relief.